22:57 , May 16, 2018 |  BC Extra  |  Company News

Management tracks: Novartis, Aileron

Novartis AG (NYSE:NVS; SIX:NOVN) said General Counsel Felix Ehrat will retire, effective June 1, in light of Novartis' payments to a consultancy owned by Michael Cohen. "As a co-signatory with our former CEO, I take...
15:22 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Viracta starts Phase Ib/II of VRx-3996 for Epstein-Barr virus-positive lymphomas

Viracta Therapeutics Inc. (San Diego, Calif.) began the Phase Ib/II VT3996-201 trial of VRx-3996 (chr-3996) in combination with valganciclovir to treat Epstein-Barr virus-positive lymphomas. The open-label, U.S. trial is enrolling up to 40 patients. The trial’s...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
22:01 , Apr 7, 2017 |  BioCentury  |  Finance

Combo quest

By leading Viracta Therapeutics Inc.’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal. Wicklow Capital,...
19:43 , Apr 7, 2017 |  BC Week In Review  |  Company News

Viracta, NantKwest deal

Viracta granted NantKwest exclusive, worldwide rights to develop and commercialize VRx-3996 in combination with its portfolio of natural killer (NK) cell therapies. Viracta is eligible for development and commercial milestones plus royalties. Viracta said it...
04:23 , Apr 7, 2017 |  BC Week In Review  |  Financial News

Viracta completes venture financing

On April 4, cancer company Viracta Therapeutics Inc. (San Diego, Calif.) raised an undisclosed amount in the first close of an $18.4 million series B round led by new investor NantKwest Inc. New investor Wicklow...
14:38 , Apr 4, 2017 |  BC Extra  |  Financial News

Viracta raises $18.4M, strikes NantKwest deal

Viracta Therapeutics Inc. (San Diego, Calif.) closed the first tranche of an $18.4 million series B round led by new investor NantKwest Inc. (NASDAQ:NK). New investor Wicklow Capital and existing investors Latterell Venture Partners and...
18:53 , Jan 6, 2017 |  BioCentury  |  Product Development

Viral vulnerability

Persistent viral infection, even those that are undetectable or asymptomatic, can cause some cancers and contribute to their severity. Viracta Therapeutics Inc. is treating virus-associated cancers by forcing them to re-express latent viral proteins that...